Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253733 · ClinicalTrials.gov registry record · NA
MD2Me - Texting to Promote Chronic Disease Management
A NA study, sponsored by Huang, Jeannie, M.D..
- Completed
- Registry status
- NA
- Development phase
- 81
- Enrollment target
NCT01253733: Completed NA study, sponsored by Huang, Jeannie, M.D..
NCT01253733 is a NA study that has completed, run by Huang, Jeannie, M.D.. The registered enrollment target is 81 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01253733, a NA study, has completed, sponsored by Huang, Jeannie, M.D..
- COMPLETED
- Registry status
- NA
- Development phase
- 81 participants
- Enrollment target
Study Summary
UCSD researchers are conducting a study aimed to develop and evaluate a chronic disease self management web and text message based program on health-related self-efficacy and frequency of adolescent-conducted healthcare interactions. We hypothesize that users of the program will demonstrate greater gains between baseline and 8 month measures of health related self-efficacy and adolescent-conducted healthcare interactions as compared to the usual care comparison group.
Primary Outcome
The primary aim of the study will be to develop and test the effect of a texting intervention TAHLC on health-related self-efficacy and frequency of adolescent-conducted healthcare interactions over the study period of 8 months.
Interventions
- BEHAVIORAL MD2ME
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-03 |
| Phase | NA |
What the finished NCT01253733 record still lists
NCT01253733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which MD2ME is the first listed.
NCT01253733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01253733 about?
NCT01253733 is a clinical study titled "MD2Me - Texting to Promote Chronic Disease Management". UCSD researchers are conducting a study aimed to develop and evaluate a chronic disease self management web and text message based program on health-related self-efficacy and frequency of adolescent-conducted healthcare interactions. We hypothesize that users of the program will demonstrate greater ...
What is the current status of trial NCT01253733?
This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2009-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01253733?
The interventions under investigation include: MD2ME (BEHAVIORAL).
Who is sponsoring clinical trial NCT01253733?
This trial is sponsored by Huang, Jeannie, M.D., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01253733's enrollment target sits among peer trials
81 992nd of 2000 higher than 1,007 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia